On June 22, Qingsong Health rose 8.08% in regular trading, trading at HKD 14.8/share, with turnover of HKD 102 million. The rally was driven by the announcement of a strategic cooperation agreement with Shanghai Pharma Holdings (Hunan) Biological Products Co., Ltd.

Under the agreement, both parties will leverage Qingsong Health's proprietary evidence-based medicine AI agent \"ZhengYuanFang\" as the core technology platform to build an intelligent screening, differential diagnosis, medication guidance, and full-cycle health management service system for rare diseases. The partnership aims to construct a complete ecosystem loop integrating pharmaceutical distribution, medical services, and insurance payment.

This marks a further expansion of the company's AI technology into pharmaceutical supply chain applications. Earlier on June 18, the company released \"ZhengJing,\" the world's first evidence-based medicine AI glasses system at CES Asia, which drove the stock up over 25%. The company had also previously signed a health management service cooperation agreement with Yingda Life Insurance. The latest partnership signals an accelerating pace of commercial deployment across multiple verticals.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)